Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)A Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets/vial) 420vials,and 50 other contracts

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Jan 22, 2024
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Niigata
Classification
0004 Medical & Pharmaceutical Products
Summay of notice ⑴ Official in charge of disbursement of the procuring entity : Tatsuo Ushiki, President, National University Corporation Niigata University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets/vial) 420vials
B Letermovir (240㎎ 14tablets/case) 300 cases
C Olaparib (100㎎ 56tablets/case) 140 cases
D Olaparib (150㎎ 56tablets/case) 420 cases
E Aflibercept (Genetical Recombination) (2㎎ 0.05mL/syringe) 480syringes
F Vutrisiran Sodium Kit (25㎎ 0.5mL/syringe) 4syringes
G Tocilizumab (Genetical Recombination) (200㎎ 10mL/vial) 1,320vials
H Tocilizumab (Genetical Recombination) (162㎎ 0.9mL/kit) 1,080cases
I Paclitaxel (100㎎/vial) 1,300vials
J Cetuximab (Genetical Recombination) (100㎎ 20mL/vial) 1,350vials
K Bevacizumab (Genetical Recombination) (100㎎ 4mL/vial) 870vials
L Bevacizumab (Genetical Recombination) (400㎎ 16mL/vial) 1,100vials
M Durvalumab (Genetical Recombination) (120㎎ 2.4mL/vial) 460vials
N Durvalumab (Genetical Recombination) (500㎎ 10mL/vial) 450vials
O Canakinumab (Genetical Recombination) (150㎎ 1mL/vial) 30vials
P Nivolumab (Genetical Recombination) (100㎎ 10mL/vial) 210vials
Q Abatacept (Genetical Recombination) (250㎎/vial) 500vials
R Nivolumab (Genetical Recombination) (240㎎ 24mL/vial) 970vials
S Trastuzumab emtansine (Genetical Recombination) (100㎎/vial) 120vials
T Pembrolizumab (Genetical Recombination) (100㎎ 4mL/vial) 2,530vials
U Patisiran Sodium (8.8㎎ 4.4mL/vial) 30vials
V Burosumab (Genetical Recombination) (30㎎ 1mL/vial) 30vials
W Freeze-dried polyethylene glycol treated human normal immunoglobulin (5g 100mL/vial (with soluation)) 900vials
X Polyethylene glycol treated human normal immunoglobulin (10g 100mL/vial) 860vials
Y Tisagenlecleucel 3sets
Z Ramucirumab (Genetical Recombination) (500㎎ 50mL/vial) 110vials
AA Palivizumab (Genetical Recombination) (100㎎ 1mL/vial) 480vials
AB Ustekinumab (Genetical Recombination) (45㎎ 0.5mL/syringe) 560syringes
AC Asfotase alfa (Genetical Recombination) (28㎎ 0.7mL/vial) 120vials
AD Asfotase alfa (Genetical Recombination) (80㎎ 0.8mL/vial) 390vials
AE Pegfilgrastim (Genetical Recombination) (3.6㎎ 0.36mL/syringe) 670syringes
AF Nusinersen Sodium (12㎎ 5mL/vial) 6vials
AG Imiglucerase (Genetical Recombination) (400units/vial) 150vials
AH Lanreotide Acetate (120㎎/syringe) 130syringes
AI Daratumumab (Genetical Recombination) (400㎎ 20mL/vial) 200vials
AJ Atezolizumab (Genetical Recombination) (1,200㎎ 20mL/vial) 420vials
AK Mepolizumab (Genetical Recombination) (100㎎ 1mL/kit) 390kits
AL Pertuzumab (Genetical Recombination) (420㎎ 14mL/vial) 220vials
AM Avelumab (Genetical Recombination) (200㎎ 10mL/vial) 290vials
AN Blinatumomab (Genetical Recombination) (35㎍/vial (with infusion stabilization liquid)) 200vials
AO Adalimumab (Genetical Recombination) (40㎎ 0.4mL/syringe) 470syringes
AP Benralizumab (Genetical Recombination) (30㎎ 1mL/syringe) 100syringes
AQ Sugammadex Sodium (200㎎ 10mL 10vials/case) 330cases
AR Remdesivir (100㎎/vial) 420vials
AS Ipilimumab (Genetical Recombination) (50㎎ 10mL/vial) 70vials
AT Ravulizumab (Genetical Recombination) (300㎎ 3mL/vial) 650vials
AU Dinutuximab (Genetical Recombination) (17.5㎎ 5mL/vial) 60vials
AV Denosumab (Genetical Recombination) (120㎎ 1.7mL/vial) 1,080vials
AW Elapegademase (Genetical Recombination) (2.4㎎ 1.5mL/vial) 50vials
AX Infliximab (Genetical Recombination) (100㎎/vial) 1,590vials
AY Romiplostim (Genetical Recombination) (250㎍/vial) 1,240vials
⑷ Delivery period : From 1 April, 2024 through 31 March, 2025
⑸ Delivery place : Niigata University Medical and Dental Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B have the Grade A or Grade B qualification during fiscal 2023 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C prove to have obtained license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University,
E meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article 5 of the Regulation,
F not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University.
⑺ Time limit of tender : 17 : 15 14 March, 2024
⑻ Contact point for the notice : Hiromasa Kawada, Procurement Section, Niigata University Medical and Dental Hospital, 754 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951-8520 Japan, TEL 025-227-2430
⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.